Ticker

Celldex Therapeutics NASDAQ: CLDX reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.

Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups Clinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU and patients with severe disease or severe angioedema…

Constellation Software TSE: CSU used its second-quarter conference call to outline its approach to artificial intelligence, vertical-market organization and acquisitions, while executives addressed recent organic-growth pressure tied to several acquired businesses and comparison effects.

MIAMI--(BUSINESS WIRE)--CSU Digital is Latin America's largest independent card processor, managing more than 50 million cards and processing nearly $100 billion in annual transactions. This week, the company brought its U.S. expansion plans into focus at its executive summit at The Plaza Hotel in New York City, drawing senior payments, banking and fintech leaders for a half-day of discussion on the state of U.S.…

HCI, PGR, ALL and PLMR are positioned to stay resilient as CSU sees a milder 2026 hurricane season, prudent pricing, increased exposure and increased digitalization.